Clinical Applications of Adoptive Natural Killer Cell Immunotherapy for Cancer: Current Status and Future Prospects

被引：6
|
作者：
Guo, Hongfeng [1 ]
Qian, Xifeng [1 ]
机构：
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, Wuxi, Peoples R China
来源：
ONKOLOGIE | 2010年 / 33卷 / 07期
关键词：
Natural killer cells; alloreactivity; Adoptive immunotherapy; KIR LIGAND INCOMPATIBILITY; HIGH-DOSE INTERLEUKIN-2; ALLOGENEIC NK CELLS; UNRELATED DONOR; MISSING SELF; HEMATOPOIETIC TRANSPLANTATION; CYTOTOXICITY RECEPTORS; INHIBITORY RECEPTORS; MEDIATED CYTOLYSIS; MYELOID-LEUKEMIA;
D O I：
10.1159/000315698
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Natural killer (NK) cells are cytotoxic and cytokine-producing lymphocytes involved in the immune defense against viral infections and tumors. NK cells activated with cytokines, such as interleukin-2, have been used since the 1980s as adoptive immunotherapy against cancer. NK cell alloreactivity has been demonstrated to enhance control of acute myeloid leukemia relapse and greatly reduce the risk of graft-versus-host disease in HLA haplotype-mismatched hematopoietic transplantation, and has been explored as a tool for adoptive immunotherapy for cancer patients. Future manipulation to improve NK cell adoptive immunotherapy by means of increasing target recognition and reducing inhibitory signaling is being explored.
引用
收藏
页码：389 / 395
页数：7
相关论文
共 50 条
  • [31] Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma
    Nguyen, Tu
    Chen, Po -Chun
    Pham, Janet
    Kaur, Kawaljit
    Raman, Steven S.
    Jewett, Anahid
    Chiang, Jason
    [J]. CRITICAL REVIEWS IN IMMUNOLOGY, 2024, 44 (05)
  • [32] ADOPTIVE IMMUNOTHERAPY OF CANCER - ACCOMPLISHMENTS AND PROSPECTS
    ROSENBERG, SA
    [J]. CANCER TREATMENT REPORTS, 1984, 68 (01): : 233 - 255
  • [33] Improving natural killer cell cancer immunotherapy
    Berrien-Elliott, Melissa M.
    Romee, Rizwan
    Fehniger, Todd A.
    [J]. CURRENT OPINION IN ORGAN TRANSPLANTATION, 2015, 20 (06) : 671 - 680
  • [34] Current status of adoptive immunotherapy of malignancies
    Morse, MA
    Clay, TM
    Lyerly, HK
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) : 237 - 247
  • [35] Natural killer cell-related anti-tumour adoptive cell immunotherapy
    Qi, Yuwen
    Li, Ying
    Wang, Hua
    Wang, Anjin
    Liu, Xuelian
    Liang, Ziyan
    Gao, Yang
    Wei, Liqing
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2024, 28 (11)
  • [36] Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects
    Zhang, Jing-Shun
    Sun, Yuan-Dong
    Li, Yuan-Min
    Han, Jian-Jun
    [J]. HELIYON, 2024, 10 (16)
  • [37] IMMUNOTHERAPY OF CANCER USING INTERLEUKIN-2 - CURRENT STATUS AND FUTURE-PROSPECTS
    ROSENBERG, SA
    [J]. IMMUNOLOGY TODAY, 1988, 9 (02): : 58 - 62
  • [38] Immunotherapy for Malignant Pleural Mesothelioma Current Status and Future Prospects
    Wong, Raymond M.
    Ianculescu, Irina
    Sharma, Sherven
    Gage, Diana L.
    Olevsky, Olga M.
    Kotova, Svetlana
    Kostic, Marko N.
    Grundfest, Warren S.
    Hou, Dongmei
    Cameron, Robert B.
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2014, 50 (05) : 870 - 875
  • [39] Clinical cancer immunotherapy: Current progress and prospects
    Liu, Chenglong
    Yang, Mengxuan
    Zhang, Daizhou
    Chen, Ming
    Zhu, Di
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Immunotherapy for Prostate Cancer: Current Indications and Future Prospects
    Small, Eric J.
    [J]. HUMAN GENE THERAPY, 2010, 21 (10) : 1379 - 1379
12345